07:00 , May 5, 2014 |  BC Week In Review  |  Company News

ALK-Abello, Eddingpharm sales and marketing update

Eddingpharm received exclusive rights to market ALK-Abello's house mite allergy products Soluprick SQ and Alutard SQ in China. The deal will initially run for seven years, provided undisclosed performance targets are met. Soluprick...
07:00 , Mar 17, 2014 |  BioCentury  |  Finance

Circassia raises expectations

The largest-ever European biotech IPO - by Circassia Pharmaceuticals plc - plus three new filings have buysiders thinking the crack in a European IPO window could be widening. But if Circassia doesn't perform, it could...
07:00 , Aug 20, 2007 |  BC Week In Review  |  Clinical News

Alutard SQ inflammation data

Data published in the European Journal of Allergy and Clinical Immunology showed that the allergy vaccine Alutard significantly reduced the risk of developing asthma at 10 years. In the European PAT study in subjects with...
08:00 , Mar 17, 2003 |  BC Week In Review  |  Clinical News

Alutard SQ: Phase III data; Marketed outside the U.S. to treat pollen, dust mite, animal hair, insect sting and grass allergies

In a double-blind, placebo-controlled U.K. Phase III trial in 410 patients, those given Alutard had reduced allergy symptoms and rated their average symptom score >30% lower than that of placebo patients. Alutard patients also used...
07:00 , Aug 16, 1999 |  BC Week In Review  |  Clinical News

Alutard SQ: Marketed

Researchers published in The New England Journal of Medicine a study of 32 patients successfully treated with the vaccine for three years, showing that seasonal symptom scores and the use of antiallergic medication remained low...